Welcome to our dedicated page for Century Therapeutics SEC filings (Ticker: IPSC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Century Therapeutics, Inc. (NASDAQ: IPSC) SEC filings page on Stock Titan provides access to the company’s official U.S. regulatory documents, including Forms 10-K, 10-Q, 8-K and other submissions. These filings offer detailed information on Century Therapeutics’ iPSC-derived cell therapy pipeline, financial position and material corporate events.
Century Therapeutics uses its SEC reports to describe its focus on autoimmune diseases, cancer and Type 1 diabetes, its Allo-Evasion™ immune evasion technology, and programs such as CNTY-101, CNTY-308 and CNTY-813. Current reports on Form 8-K have disclosed items like private placement financing arrangements, Nasdaq listing status developments, workforce reductions, board and executive changes, and earnings press releases.
Through periodic filings such as Forms 10-Q and 10-K, investors can review Century Therapeutics’ reported cash, cash equivalents and investments, research and development and general and administrative expenses, collaboration revenue recognition and accumulated deficit. Risk factor and business sections in these reports provide the company’s own discussion of uncertainties related to clinical development, regulatory approvals, collaborations and market conditions.
Stock Titan enhances this information with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand the implications of new documents. Real-time updates from EDGAR ensure that new IPSC filings, including 8-Ks on material events and any Form 4 insider transaction reports, are added as they become available. Use this page to navigate directly to the filings most relevant to your analysis of Century Therapeutics’ business, pipeline and capital structure.
Century Therapeutics insider filing reports a grant of restricted stock units to the company’s Chief Scientific Officer. The report shows 762,543 RSUs were granted on 09/18/2025; each RSU represents a contingent right to one share of common stock and will be settled in shares on each vesting date. The RSUs vest 50% on October 1, 2026 and the remaining 50% on October 1, 2027, subject to continued service. After the grant the reporting person beneficially owns 992,489 shares directly and 10,697 shares indirectly via the Cowan Investment Nominee Trust, which the filer disclaims except for any pecuniary interest.
Douglas Carr, SVP Finance & Operations reported a small, automated sale of company stock to cover tax withholding related to restricted stock unit vesting. On 09/08/2025 he disposed of 263 shares of Century Therapeutics, Inc. (IPSC) at $0.50 per share, leaving 405,423 shares beneficially owned in a direct capacity.
The Form 4 states the sales were automatic and not at the reporting person’s discretion, made solely to satisfy tax-withholding obligations. The filing is signed by the reporting person on 09/10/2025.
Brent Pfeiffenberger, President and CEO and Director of Century Therapeutics, Inc. (IPSC), reported a small automatic sale of common stock on 09/08/2025 to satisfy tax withholding related to the vesting of restricted stock units. The Form 4 shows 488 shares were sold at $0.50 per share, and following the reported transaction the reporting person beneficially owns 3,268,909 shares, held directly. The filing states the sales were automatic to cover tax obligations and not at the reporting person’s discretion.
Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics, Inc. (IPSC), reported transactions on Form 4 showing an automatic sale of 539 shares of common stock on 09/08/2025 at a price of $0.50 per share to satisfy tax withholding related to the vesting of restricted stock units. After the reported sale, Mr. Russotti is shown as directly owning 391,508 shares and indirectly owning 92,773 shares through the Gregory Russotti 2021 Family Trust. The filing was signed by an attorney-in-fact on 09/10/2025. The Form 4 notes the sales were automatic and not made at the reporting person's discretion.
Century Therapeutics (IPSC) filed a Form 144 reporting a proposed sale of 488 shares of common stock through Fidelity Brokerage Services with an aggregate market value of $243.95. The shares were acquired on 09/05/2025 as a restricted stock vesting event and payment is listed as compensation. The filer indicates the approximate date of sale as 09/08/2025 and cites NASDAQ as the exchange. The filing also discloses two sales by the same person in the past three months: 475 shares sold on 06/09/2025 for $295.50 and 30,745 shares sold on 08/18/2025 for $17,521.58. The notice includes the standard representation that the seller has no undisclosed material adverse information.
Century Therapeutics, Inc. (IPSC) Form 144 notice reports a proposed sale of 539 shares of common stock held by an individual through Fidelity Brokerage Services, with an aggregate market value of $269.45 and an approximate sale date of 09/08/2025 on NASDAQ. The securities were acquired on 09/05/2025 through restricted stock vesting from the issuer and were paid as compensation. The filer also reports prior dispositions in the past three months: 526 shares sold on 06/09/2025 for gross proceeds of $327.22. The notice includes the filer’s certification that no undisclosed material adverse information is known.
Century Therapeutics, Inc. received a deficiency letter from Nasdaq after its closing bid price fell below the $1.00 minimum over the last 30 consecutive business days, triggering a 180-day compliance period that ran to August 26, 2025. Nasdaq determined the company otherwise met market value and initial listing requirements for The Nasdaq Capital Market and accepted the company's plan to cure the deficiency, including a possible reverse stock split. On August 27, 2025 Nasdaq approved Century's transfer from The Nasdaq Global Select Market to The Nasdaq Capital Market and the company's common stock continues to trade under the symbol IPSC. The filing notes the transfer became effective at the opening of business on August 27, 2025, although one date in the text appears truncated.
Century Therapeutics (IPSC) filing notifies a proposed sale under Rule 144 of 30,745 common shares with an aggregate market value of $17,521.58. The shares represent restricted stock that vested and were acquired on 08/15/2025 and the filer intends to sell on or about 08/18/2025 through Fidelity Brokerage Services on NASDAQ. The filing shows 86,389,098 shares outstanding for the issuer. It also discloses a prior sale by the same person of 475 shares on 06/09/2025 for $295.50. The acquisition payment is listed as compensation. The signer certifies no undisclosed material adverse information.
Brent Pfeiffenberger, President and CEO and a director of Century Therapeutics, Inc. (IPSC), received a grant of 1,587,614 restricted stock units (RSUs) on 08/14/2025. Each RSU converts into one share of common stock and will settle in shares on vesting. The RSUs vest 50% on August 14, 2027 and the remaining 50% on August 14, 2028, each tranche conditioned on continued service through the vesting date. The reported transaction shows an acquisition at a reported price of $0 and indicates 3,269,397 shares beneficially owned by the reporting person after the transaction. The Form 4 was filed for this single reporting person and signed by an attorney-in-fact on 08/18/2025.
Century Therapeutics (IPSC) reported operational updates reflecting continued development of its iPSC-derived cell therapy pipeline and recent acquisition activity. The company disclosed 86,322,071 shares outstanding at June 30, 2025 versus 85,836,429 at December 31, 2024. Century completed the acquisition of Clade, issuing 3,741,646 common shares at close and recording holdback shares of up to 793,687 subject to indemnification adjustments. Contingent consideration at closing included a fair-value amount of $2,600 plus a potential Clade milestone valued at $8,883, and a possible milestone payment of $10,000 payable in cash, shares, or combination.
The filing outlines program progress and capabilities including lead candidate CNTY-101, preclinical programs from Clade, and additional CAR-iT candidates (CNTY-308, CNTY-341) using the company’s Allo-Evasion™ and iPSC platforms. The company reported prior ATM sales of 4,084,502 shares for net proceeds of $17,829 in the six months ended June 30, 2024 and no ATM sales in the six months ended June 30, 2025. Quarter-over-quarter operating expense shifts include G&A of $7.8M versus $8.3M in the prior-year quarter and mixed R&D and facility cost changes driven by staff reductions, consolidation of lab operations, and completion of a manufacturing campaign under the FCDI collaboration.